Even though NfL reduction in CSF had been reported in a few studies of SMA patients on nusinersen, NfL, in general, does not seem to represent a reliable biomarker to monitor the response of SMA patients to nusinersen treatment. This evidence concerns the gene NEFL and proximal spinal muscular atrophy.